Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)
A review of pharma and biotech equity market, IPO, and M&A trends and disruptions through the first half of 2022 and the implications for the future.
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Pharm Exec: China Invests in Building Biotech (Young & Partners comments – January 2022)
Young & Partners comments on what to expect from China in this article
Chemicals M&A to be resilient in 2022 (ICIS Chemical Business February 11 – February 17 2022)
Young & Partners reviews the developments through yearend and the outlook for 2022
New Supply Chains (ICIS Chemical Business November 26 – December 2 2021)
Takeaways from Senior Chemical Executive Conference Panel on Reimagining Supply Chain Strategies
Chemical Economic, M&A and Financing (ICIS Chemical Business November 19-26 2021)
Comprehensive look at the economic, stock market, M&A and financing trends and outlook
Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)
While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable
Mixed outlook for chemical financing (ICIS Chemical Business August 27, 2021)
Young & Partners documents slower, but still healthy debt and equity issuance
Chemical M&A market in transition (ICIS Chemical Business August 20, 2021)
Slow M&A market begins to pick up, but with many underlying changes